Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 12, 2025eGastroenterologyOpen Access

Steatotic liver disease and cancer: from pathogenesis to therapeutic targets

View Full Paper
Ask AI
Bookmark
Share

Authors

ZYZhihong YangZLZhenjie LiuWLWanqing Liu

Discussion

Loading...

Member takes

Overview

Review discusses metabolic dysfunction-associated steatotic liver disease outcomes in patients, suggesting targeted therapies.

Key Points

  • Increasing prevalence of metabolic dysfunction-associated steatotic liver disease highlights urgent need for research.
  • Multiple genetic variants have been identified as risk factors for steatotic liver disease, influencing its progression.
  • Therapeutics for steatotic liver disease include hormone receptor agonists and other targeted treatments.
  • Cirrhosis and liver cancer are potential complications of steatotic liver disease, necessitating tailored intervention strategies.

Cite This Study

Yang et al. (2025) studied this question.

synapsesocial.com/papers/68d44c5531b076d99fa563bdhttps://doi.org/10.1136/egastro-2025-100218
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prevention and control of risk factors in metabolic and alcohol-associated steatotic liver disease2024 · 7 citations
  2. 2Genetic risk of steatotic liver disease: Pathogenesis, prognosis, and implications for treatment2026 · 2 citations
  3. 3Precision pathophysiology in steatotic liver disease2026 · 1 citations
  4. 4Therapeutic Landscape Evolution: From Lifestyle Interventions to Precision Pharmacotherapy2026
  5. 5Steatotic Liver Disease: Non-Invasive Assessment and Biomarkers Across MASLD, MetALD and ALD2026